Irvine Clinical Research reposted this
Delighted to have contributed to this Alzheimer's Disease trial, which led to FDA approval of an updated label. As I mentioned in this press release, this updated dosing strategy is a meaningful advancement for patients and their care teams. By significantly reducing the risk of ARIA-E, we can offer patients and care teams greater confidence in the safety of Kisunla while preserving its ability to reduce amyloid. Thank you to our study participants, our team, and Lilly for making this advance possible. https://lnkd.in/gsfjEiBn
